Clinical Trial Title
The purpose of this study is to test whether the drug Glucophage® XR (generic name metformin extended-release tablets) can prevent cognitive decline among persons with mild cognitive impairment.National Clinical Trial Number:
NCT04098666Contact Information
Clinical Trial Protocol Description:
The purpose of this study is to test the efficacy of the drug Glucophage® XR Metformin (generic name metformin extended-release tablets) in the prevention of cognitive decline associated with Alzheimer’s dementia. Nationwide, 370 participants will be recruited for this study at 11 sites across the United States. At ÍÑÒÂÖ±²¥, we expect to recruit up to 30 participants.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Be 55-90 years old.
- Have a diagnosis of MCI or a subjective memory complaint.
- You have not been diagnosed with diabetes or dementia.
- Have an individual who knows you well willing to take part in the study with you as your study partner.
This is a partial list of inclusion and exclusion criteria.
Study Details
Clinical Trial Investigator
Zoe Arvanitakis, PhD
Contact Information
Michael Pessman
Clinical Trial Location
ÍÑÒÂÖ±²¥
Location
ÍÑÒÂÖ±²¥
1620 W Harrison St
Chicago, IL 60612